BioCentury
ARTICLE | Company News

Bio3 Research, Cephalon, Creabilis Therapeutics deal

December 12, 2005 8:00 AM UTC

CEPH received an exclusive option to develop and commercialize K252a, a preclinical kinase inhibitor to treat psoriasis and restenosis. The compound is being developed by Creabilis and Bio3. ...